18F-Fdg-Pet/Ct | 37 |
Accessory breast tissue | 1 |
Adalimumab | 94 |
Adverse event | 155 |
Aggressive | 381 |
Angiolipoma | 371 |
Angiosarcoma | 190 |
Anthracyclines | 299 |
Arab culture | 329 |
Arfi elastography | 134 |
Artificial intelligence | 203 |
Axilla | 163, 195 |
Axillary dissection | 163, 289 |
Axillary lymph node metastases | 37, 203 |
Axillary reverse lymphatic mapping | 1 |
Axillary ultrasound | 37 |
Barriers | 329 |
Benign | 248 |
Bioempedance spectroscopy | 148 |
Biomarkers | 235 |
Body mass index | 271 |
Bone metastasis | 286 |
BRCA mutations | 323 |
Breast | 30, 172, 190, 279, 343, 360, 371 |
Breast calcification | 13 |
Breast cancer | 1, 6, 63, 74, 79, 85, 91, 105, 134, 141, 148, 155, 167, 182, 199, 222, 229, 235, 252, 258, 292, 306, 315, 375 |
Breast cancer risk | 108 |
Breast cancer screening | 79 |
Breast cancer screening behaviors | 329 |
Breast cancer surgery | 55 |
Breast carcinoma | 271, 289 |
Breast carcinomas | 336 |
Breast conserving therapy | 127 |
Breast disease | 248 |
Breast imaging | 286 |
Breast implant | 381 |
Breast lesions | 48 |
Breast mass | 381 |
Breast reconstruction | 105 |
Breast ultrasonography | 163, 199 |
Breast-conserving surgery | 315 |
Breast-conserving therapy | 55 |
Breast-Q | 127 |
Cancer | 172, 203 |
Cardiotoxic agents | 299 |
Care pathway | 222 |
Case report | 94 |
Cd3D | 141 |
Chemotherapy | 289, 299 |
Chest scan | 91 |
Cholesterol | 108 |
Circumferential volume measurement | 148 |
Citation | 258 |
Clinical features | 360 |
Clinical practices | 205 |
Colonic metastasis | 375 |
Contralateral prophylactic mastectomy | 16 |
COVID-19 | 306 |
Covid-19 | 74, 85, 91, 289 |
Cystic neutrophilic granulomatous mastitis | 94 |
De novo breast cancer | 85 |
De-escalation | 6 |
Desmoid | 381 |
Diagnostic performance | 37 |
Dietary fat intake | 108 |
Direct-to-implant reconstruction | 55 |
Ductal carcinoma in situ | 205, 336 |
Ductography | 279 |
ECG | 299 |
Elastin fiber | 134 |
Estrogen receptor | 167 |
Extra-mammary | 252 |
Fat grafting | 105 |
Fibroadenoma | 134 |
Fibromatosis | 381 |
Foxo1 | 141 |
Galactocele | 102 |
Gastric metastasis | 375 |
Gastrointestinal tract metastasis | 375 |
Gata3 expression | 229 |
Genetic counseling | 16 |
Germline brca mutation | 16 |
Granulomatous mastitis | 195 |
Gynecomastia | 371 |
Hemangioma | 190 |
HER2 | 315 |
Her2 | 63 |
Hereditary breast cancer | 16 |
Histopathological findings | 360 |
Histopathology | 229 |
Hormonal therapy | 155, 292 |
Hyperprolactinemia | 102 |
Idiopathic granulomatous mastitis | 94 |
Il-2 | 141 |
Il-2Ra | 141 |
Immediate breast reconstruction | 55 |
Immunohistochemistry | 21, 229 |
Implant-based reconstruction | 55 |
In silico analysis | 235 |
In situ | 343 |
Indeterminate lesion | 252 |
Innovative approaches | 205 |
Intraductal | 371 |
Intraductal carcinoma | 343 |
Intraductal proliferations | 279 |
Invasive ductal carcinoma | 271 |
Invasive lobular carcinoma | 375 |
Invasive papillary carcinoma | 360 |
Kidney injury molecule-1 | 336 |
Lupus erythematosus | 13 |
Lupus mastitis | 13 |
Lymphedema | 148 |
Machine learning | 203 |
Magnetic resonance imaging | 172, 199 |
Male | 371 |
Male breast cancer | 199, 323 |
Malignant | 343 |
Mammography | 172, 199 |
Mastalgia | 248 |
Metastasis | 252, 286 |
Metastatic cancer | 85 |
Mir-490 | 141 |
Molecular subtype | 353 |
Molecular subtypes of breast carcinoma | 271 |
Mono-unsaturated fatty acid | 108 |
Mri | 37, 79, 190 |
Mucinous | 30 |
Mucinous carcinoma | 353 |
Mucormycosis | 289 |
Muslim Arab Iraqi women | 329 |
Neo-adjuvant therapy | 6 |
Neoadjuvant chemotherapy | 167, 271, 289 |
Neoadjuvant systemic therapy | 306 |
Neuroendocrine | 30 |
Neutrophil gelatinase-associated lipocalin | 336 |
New version | 48 |
Nfat5 | 141 |
Nipple eczema | 102 |
Oncology department | 74 |
Oncoplastic reconstruction | 127 |
Pandemic | 85 |
Panniculitis | 13 |
Papilloma | 371 |
Pathological complete response | 271 |
Pathology features | 323 |
Patient reported outcome | 155 |
Patient satisfaction | 63, 127 |
Patient-related delay time | 85 |
Personal health records | 155 |
Phldb | 235 |
Phyllodes tumors | 343 |
Positive lymph nodes | 163 |
Precision medicine | 205 |
Prediction | 203 |
Pregnancy | 195 |
Progesterone receptor | 167 |
Prognosis | 323, 336, 353 |
Programmed cell death protein 1 (Pd-1) | 21 |
Programmed death-ligand 1 (Pd-L1) | 21 |
Quality of life | 155, 292 |
Quality-of-life | 148 |
Radical lumpectomy | 127 |
Radiomics | 203 |
Receptor change | 167 |
Recurrence | 315 |
Research | 258 |
Risk factors | 79, 182 |
Risk-reducing salpingo-oophorectomy | 16 |
Sars-Cov-2 | 74, 91 |
Saturated fatty acid | 108 |
Screening | 16, 91, 182 |
Sentinel lymph node biopsy | 37 |
Sentinel node biopsy | 163 |
Solid papillary | 30 |
Staff viewpoint | 222 |
Stereotactic core-needle biopsy | 279 |
Subcutaneous | 63 |
Success factors | 222 |
Superb microvascular imaging | 48 |
Surgery | 195, 306 |
Survey | 205 |
Survival | 182 |
Synchronous neoplasms | 199 |
Tertiary hospital | 74 |
Trastuzumab | 63 |
Treatment de-escalation | 205 |
Triple-negative breast cancer | 21, 315 |
Troponin I | 299 |
Tumor necrosis factor alpha inhibitor | 94 |
Turkish | 148 |
Two-stage implantbased reconstructions | 55 |
Ultrasonography | 48 |
Ultrasound | 172 |
Vus mutation | 16 |
Women | 292 |
Women’s health | 48 |